How should peripheral nerve sheath tumors be evaluated and managed, including indications for biopsy, surgical excision, radiation therapy, chemotherapy, and follow‑up?

Management of Peripheral Nerve Sheath Tumors

For peripheral nerve sheath tumors, management hinges on accurate histopathologic and molecular classification: obtain image-guided core needle biopsy (minimum 6 cores) targeting FDG-PET avid or MRI-suspicious regions for all clinically or radiologically worrisome noncutaneous lesions, followed by molecular profiling to identify CDKN2A/B inactivation (ANNUBP) or SUZ12/EED/TP53 mutations with aneuploidy (MPNST), then proceed with complete surgical excision as the only curative treatment for malignant lesions. 1

Initial Evaluation and Biopsy Indications

When to Biopsy

Biopsy is indicated for:

• Noncutaneous tumors (associated with large nerves or nerve plexi) with worrisome clinical features 1
• Rapidly enlarging masses, particularly >5 cm 2
• Presence of pain with motor and sensory deficits 2
• Increased FDG-PET avidity or decreased ADC on diffusion-weighted MRI 1
• Any lesion in NF1 patients showing concerning radiologic changes 3

Critical pitfall: MRI alone cannot definitively distinguish benign from malignant lesions—only 1 of 3 MPNSTs in one series was correctly identified on MRI preoperatively 2. Do not rely on imaging alone for tissue diagnosis.

Biopsy Technique

Use CT- or ultrasound-guided core needle biopsy rather than excisional biopsy to avoid contaminating the surgical field 2. The 2025 consensus guidelines specify 1:

• Minimum 6 core biopsies (4-8 mm each) if safe and feasible
• Target the most suspicious regions identified on FDG-PET or DWI-MRI
• Label each biopsy site clearly on containers (e.g., "region #1, FDG-PET avid")
• Process with no more than 2 cores per paraffin block to preserve tissue
• Subspecialized pathologist evaluation is essential

Warning: Sampling error is a real risk with needle biopsy due to tumor heterogeneity 4, but the alternative—excisional biopsy without knowing the diagnosis—leads to positive margins and inability to achieve adequate oncologic resection 2.

Histopathologic and Molecular Classification

Standardized Histologic Assessment

All biopsies must be evaluated for 1:

• Cytologic atypia
• Loss of neurofibromatous architecture
• Hypercellularity
• Mitotic count per 10 HPF
• Necrosis

Diagnostic Categories

Neurofibroma: Retained architecture, no atypia, no hypercellularity, inconspicuous mitoses 1

ANNUBP: Minimum 2 of the following 1:

• Cytologic atypia
• Loss of neurofibroma architecture
• Hypercellularity
• Mitotic count >1/50 HPF but <3/10 HPF

ANNUBP with increased proliferation (formerly "low-grade MPNST"): Features of ANNUBP with mitotic count 3-9/10 HPF 1. The terminology change avoids using "malignant" for tumors with uncertain biologic potential.

High-grade MPNST: Hypercellular, enlarged atypical cells in fascicles, no preserved neurofibroma architecture, large areas of necrosis, mitotic count typically ≥10/10 HPF 1

Molecular Profiling

Screen all noncutaneous neurofibromas undergoing biopsy for molecular features 1:

For ANNUBP diagnosis: Look for CDKN2A/B inactivation (homozygous or heterozygous)

For MPNST diagnosis: Identify:

• SUZ12 or EED inactivating mutations (ideally biallelic)
• TP53 inactivating mutations
• Significant aneuploidy

Recommended testing approach 1:

• Comprehensive next-generation sequencing panel with copy number and zygosity assessment (preferred)
• Alternative: Targeted panel for SUZ12/EED/TP53 plus array CGH for copy number analysis

Immunohistochemistry

Worrisome features warranting molecular assessment 1:

• Reduced SOX10 and/or S100 immunoreactivity
• Absence of CD34-positive lattice-like network
• Complete loss of p16 expression (suggests CDKN2A/B deletion)
• Complete H3K27me3 loss (suggests PRC2 alterations)
• Increased p53 immunoreactivity or null pattern
• Increased Ki-67 labeling index

Surgical Management

Benign Tumors (Schwannomas, Neurofibromas)

Excision biopsy preserving nerve function may be performed for symptomatic benign tumors 4. Surgical technique should include 5:

• Intraoperative nerve monitoring (used in 55% of cases in one series)
• Magnification and microsurgical instruments
• Enucleation from tumor capsule where applicable
• Epineural or fascicular repair when needed
• Tourniquet control for extremity lesions

Malignant Tumors (MPNST)

Complete surgical excision with clear margins is the only curative treatment 4, 6.

Neoadjuvant therapy considerations 7, 3:

• Neoadjuvant radiation or chemotherapy should be considered if:
  • High risk for metastatic disease
  • Downstaging needed to facilitate resection
  • Tumor is large or in critical anatomic location
• Early diagnosis via preoperative biopsy enables neoadjuvant therapy planning 3

Surgical principles:

• Achieve R0 resection (negative margins)
• Do not perform excisional biopsy without knowing diagnosis—this contaminates the field and makes adequate oncologic resection impossible 2
• If initial surgery had positive margins, re-resection may not be feasible if surgical field boundaries cannot be defined 2

Radiation Therapy

Adjuvant radiation is recommended for 7, 6:

• Larger lesions
• More aggressive histology
• High-grade tumors

Neoadjuvant radiation should be considered for resectable recurrent disease if not previously given 7

For unresectable disease: Definitive high-dose RT with tissue displacement spacers to protect bowel 7

Important limitation: For R1/R2 resections in retroperitoneal sarcomas, adjuvant RT should not be administered routinely except in highly selected patients where local recurrence would cause undue morbidity 7

Chemotherapy

Adjuvant/Neoadjuvant Setting

• Consider for high risk of metastatic disease or when downstaging needed 7
• Not recommended for low-grade tumors 7
• Regimens extrapolated from extremity soft tissue sarcoma data 7

Metastatic/Unresectable Disease

• Most active regimen: AIM (doxorubicin/ifosfamide/mesna) 7
• Targeted therapies based on Ras pathway activation have been trialed without proven benefit to date 6
• Novel combination therapies are subject of ongoing trials 6

Prognosis remains poor: 5-year survival 15-50%, particularly dismal in NF1 patients 4, 2

Follow-Up Surveillance

After management of primary disease 7:

• Every 3-6 months for 2-3 years: Physical exam with chest/abdominal/pelvic CT (preferred) or MRI
• Every 6 months for next 2 years
• Annually thereafter

Recurrent Disease

For resectable recurrence 7:

• Consider biopsy if diagnosis not clinically definitive
• Surgery to obtain oncologically appropriate margins
• Consider neoadjuvant RT (if not previously given) or systemic therapy
• Adjuvant systemic therapy for high metastatic risk or multiple recurrences

For unresectable/stage IV recurrence: Manage as unresectable disease with systemic therapy, RT, or palliative care 7

Special Considerations for NF1 Patients

The 2025 consensus guidelines emphasize that NF1-associated tumors require heightened vigilance 1:

• Higher risk of malignant transformation in neurofibromas (remote risk in schwannomas) 4
• Molecular screening recommended for all noncutaneous neurofibromas undergoing biopsy 1
• ANNUBP and MPNST often arise from preexisting lower-grade lesions 1
• Intratumoral heterogeneity complicates classification 1

Critical point: The constellation of enlarging mass >5 cm + pain + motor and sensory deficits should raise high suspicion for MPNST in NF1 patients 2.